Pacira to Acquire MyoScience to Expand its Post-Surgical Portfolio

Shots:

• Pacira acquires MyoScience, in all stock transaction for $220M. MyoScience to receive $120M upfront and $100M as regulatory and commercial milestones. The transaction is expected to close in Apr’2019
• The focus of an acquisition is to strengthen Pacira’s footprints in post-surgical analgesics by adding Myoscience’s iovera system to Pacira’s lead candidate Exparel
• Pacira is planning to change its name to Pacira BioSciences, Inc. to reflect its broad portfolio and expect to complete the acquisition in H2’20

Click here to read full press release/ article | Ref: Pacira | Image: MassDevice